↓ Skip to main content

American Association for Cancer Research

Article Metrics

Cabozantinib in Combination with Immunotherapy for Advanced Renal Cell Carcinoma and Urothelial Carcinoma: Rationale and Clinical Evidence

Overview of attention for article published in Molecular Cancer Therapeutics, December 2019
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (95th percentile)
  • High Attention Score compared to outputs of the same age and source (98th percentile)

Mentioned by

twitter
75 tweeters

Citations

dimensions_citation
10 Dimensions

Readers on

mendeley
27 Mendeley
Title
Cabozantinib in Combination with Immunotherapy for Advanced Renal Cell Carcinoma and Urothelial Carcinoma: Rationale and Clinical Evidence
Published in
Molecular Cancer Therapeutics, December 2019
DOI 10.1158/1535-7163.mct-18-1399
Pubmed ID
Authors

Paulo Bergerot, Peter Lamb, Evelyn Wang, Sumanta K. Pal

Twitter Demographics

The data shown below were collected from the profiles of 75 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 27 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 27 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 7 26%
Student > Master 3 11%
Student > Bachelor 2 7%
Student > Doctoral Student 2 7%
Lecturer 2 7%
Other 4 15%
Unknown 7 26%
Readers by discipline Count As %
Medicine and Dentistry 5 19%
Agricultural and Biological Sciences 4 15%
Biochemistry, Genetics and Molecular Biology 3 11%
Pharmacology, Toxicology and Pharmaceutical Science 3 11%
Chemical Engineering 1 4%
Other 2 7%
Unknown 9 33%

Attention Score in Context

This research output has an Altmetric Attention Score of 46. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 11 February 2021.
All research outputs
#534,113
of 17,020,562 outputs
Outputs from Molecular Cancer Therapeutics
#60
of 3,185 outputs
Outputs of similar age
#19,676
of 398,342 outputs
Outputs of similar age from Molecular Cancer Therapeutics
#2
of 76 outputs
Altmetric has tracked 17,020,562 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 96th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,185 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 7.5. This one has done particularly well, scoring higher than 98% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 398,342 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 95% of its contemporaries.
We're also able to compare this research output to 76 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 98% of its contemporaries.